Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Opat

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
British Journal of Haematology|July 30, 2016
High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphomaChan Yoon Cheah, David Joske, Gavin Cull, et al.
Internal Medicine Journal|March 18, 2009
The thrombotic thrombocytopenic purpura registry: a new national resource to inform patient care and medical researchM N Polizzotto, L E Phillips, P Cannell, et al.
Internal Medicine Journal|July 5, 2012
High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemiaM Low, D Lee, J Coutsouvelis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myelomaMark A Dawson, Stephen S Opat, Yamna Taouk, et al.
Hemasphere|November 15, 2019
Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDSGareth P Gregory, Michael Dickinson, Costas K Yannakou, et al.
Blood Advances|January 4, 2018
Bortezomib-based antibody depletion for refractory autoimmune hematological diseasesSumita Ratnasingam, Patricia A Walker, Huy Tran, et al.
Blood Advances|March 22, 2023
Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphomaMaciej Tatarczuch, Mark Waltham, Jake Shortt, et al.
Internal Medicine Journal|July 12, 2016
Timely initiation of chemotherapy: a systematic literature review of six priority cancers - results and recommendations for clinical practiceM Alexander, R Blum, K Burbury, et al.
Internal Medicine Journal|August 25, 2016
Guidelines for timely initiation of chemotherapy: a proposed framework for access to medical oncology and haematology cancer clinics and chemotherapy servicesM Alexander, R Beattie-Manning, R Blum, et al.
Blood Advances|September 9, 2025
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN studyRamón García-Sanz, Roger G Owen, Wojciech Jurczak, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
British Journal of Haematology|July 30, 2016
High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphomaChan Yoon Cheah, David Joske, Gavin Cull, et al.
Internal Medicine Journal|March 18, 2009
The thrombotic thrombocytopenic purpura registry: a new national resource to inform patient care and medical researchM N Polizzotto, L E Phillips, P Cannell, et al.
Internal Medicine Journal|July 5, 2012
High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemiaM Low, D Lee, J Coutsouvelis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myelomaMark A Dawson, Stephen S Opat, Yamna Taouk, et al.
Hemasphere|November 15, 2019
Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDSGareth P Gregory, Michael Dickinson, Costas K Yannakou, et al.
Blood Advances|January 4, 2018
Bortezomib-based antibody depletion for refractory autoimmune hematological diseasesSumita Ratnasingam, Patricia A Walker, Huy Tran, et al.
Blood Advances|March 22, 2023
Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphomaMaciej Tatarczuch, Mark Waltham, Jake Shortt, et al.
Internal Medicine Journal|July 12, 2016
Timely initiation of chemotherapy: a systematic literature review of six priority cancers - results and recommendations for clinical practiceM Alexander, R Blum, K Burbury, et al.
Internal Medicine Journal|August 25, 2016
Guidelines for timely initiation of chemotherapy: a proposed framework for access to medical oncology and haematology cancer clinics and chemotherapy servicesM Alexander, R Beattie-Manning, R Blum, et al.
Blood Advances|September 9, 2025
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN studyRamón García-Sanz, Roger G Owen, Wojciech Jurczak, et al.
Pageof 4